香港浸會大學
HONG KONG BAPTIST UNIVERSITY

School of 中醫藥學院
Chinese Medicine

中醫藥學院通訊
SCM NEWSLETTER

2023年7月 | JUL 2023

學院教職員榮獲傑出表現獎

SCM staff receive awards
for outstanding performance

目　錄
CONTENTS

學院教職員榮獲傑出表現獎

SCM staff receive awards for outstanding performance

香港浸會大學於5月3日舉行頒獎典禮，表揚一眾教職員的卓越表現。中醫藥學院在典禮上合共獲頒五個個人獎項，當中包括：

傑出學術研究表現獎
教學科研部中醫藥及系統生物學講座教授賈偉教授

傑出服務表現獎
臨床部中醫臨床助理教授張振海醫師

學院優秀教學表現獎
教學科研部副教授關曉儀博士

學院優秀新晉研究學者獎
教學科研部助理教授劉進博士

學院優秀指導獎
教學科研部教授韓全斌教授

臨床部兩個抗疫團隊亦獲頒「非教學人員獎勵及嘉許計劃團隊獎」，包括：

浸大中醫抗疫遠程醫療中心支援團隊

團隊由臨床部中醫臨床教授孫鋒教授帶領，成員包括臨床部藥房配藥團隊及客戶服務團隊、傳訊公關處、物業處、財務處及資訊科技處的人員

啓德暫托中心支援團隊
團隊由臨床部中醫臨床助理教授張振海醫師帶領，成員包括臨床部藥房配藥團隊、傳訊公關處、物業處、財務處、人力資源處及資訊科技處的人員

院長呂愛平教授恭賀所有獲獎教職員，並表揚他們對學院及為抗疫作出的貢獻，期望學院上下齊心，進一步提升教育、科研和醫療服務的質素，力臻至善。

Hong Kong Baptist University (HKBU) held an Awards Presentation Ceremony on 3 May to recognise the remarkable achievements of faculty members. Staff members from the School of Chinese Medicine (SCM) were presented five individual awards as follows:

President's Award for Outstanding Performance in Scholarly Work
Professor Jia Wei, Chair Professor in Chinese Medicine and Systems Biology of Teaching and Research Division (CMTR)

President's Award for Outstanding Performance in Service
Mr. Cheung Chun-hoi, Assistant Professor of Practice of Clinical Division (CLNC)

School Performance Award in Individual Teaching
Dr. Kwan Hiu-yee, Associate Professor of CMTR

School Performance Award as Early Career Researcher
Dr. Liu Jin, Assistant Professor of CMTR

School Performance Award in Research Supervision
Professor Han Quanbin, Professor of CMTR

Two anti-pandemic teams from CLNC received Team Awards under the Reward and Recognition Scheme for Non-teaching Staff. They include:

The Supporting Team for HKBU Chinese Medicine Telemedicine Centre Against COVID-19, led by Professor Sun Feng, Professor of Practice of CLNC, includes members from Dispenser Team and Customer Service Team of CLNC, as well as other service units within the university.

The Supporting Team for the Kai Tak Holding Centre, led by Mr. Cheung Chun-hoi, Assistant Professor of Practice of CLNC, members from Dispenser Team of CLNC and other service units within the university.

Professor Lyu Aiping, Dean of SCM, congratulated the award recipients and applauded their contributions to the School and the fight against the pandemic. With the joint efforts of staff members, the School will strive for excellence in teaching, research and healthcare services.

賈偉教授榮獲「傑出學術研究表現獎」

賈教授是中醫藥及系統生物學的專家，科研實力超卓。自2019年加入浸大以來，他在識別各種代謝疾病的生物標誌物，以及疾病發病過程中的關鍵代謝通路機理研究等工作上，取得重大的科研突破，贏得本地及國際讚譽。在長達30 年的學術生涯中，他所從事的尖端研究及管理轉化研究項目，碩果纍纍，獲取多項專利，為推進科學發展而做出的貢獻備受推崇。

截至2022年10月，賈教授已出版10本著作及獲得20多項專利，並在《Cell Metabolism》及《Nature Communications》等高影響力學術期刊上發表超過500篇論文。在學院任職期間發表的100篇論文中，多篇刊登在生物醫學領域中被引用次數排名在前百分之一的期刊。他的研究極具影響力，在谷歌學術的引用次數超過 34,000 次，谷歌 H 指數為 86。賈教授於2020年及2021年入選世界著名學術出版商 ELSEVIER 發布的「中國高被引學者」榜單。

賈教授目前擔任學院轄下的香港中醫藥表型組學研究中心主任，該中心是本地及全球首個研究中醫藥的表型組學中心。在他的英明領導下，該中心吸引了全球頂尖人才從事高質素的分子和群體層面轉化研究。賈教授現正牽頭成立「中國茶葉的科學評價」研究項目，為該領域的研究生提供學術及研究機會。

賈教授於 2020 年獲頒「張安德中醫藥教授」榮銜，其後不遺餘力推動學院成為世界頂尖的中醫藥研究機構。他曾領導與中國和海外知名機構及專業團體的合作項目，在國際會議和座談會上發表演講，並擔任著名科學期刊的編委。

Professor Jia Wei wins President's Award for Outstanding Performance in Scholarly Work

An expert in Chinese medicine and systems biology, Professor Jia is a highly accomplished scholar with an impressive research track record. Since joining HKBU in 2019, he has earned local and international acclaim for his work in the identification of biomarkers in various metabolic diseases, and the mechanistic studies of key metabolic pathways involved in disease pathogenesis. With a career spanning three decades, his contribution to science is evidenced by a highly respected profile in cutting-edge research, patent awards and managing translational research programmes.

As of October 2022, Professor Jia has published 10 books, secured over 20 patents and produced more than 500 papers in high-impact academic journals, including *Cell Metabolism* and *Nature Communications*. Among the 100 papers published during his tenure at SCM, many have been among the top 1% of most-cited journals in the field of biomedical sciences. The exceptional impact of his work is demonstrated by a Google Scholar citation count of over 34,000 and a Google H-Index of 86. Professor Jia was selected as one of the Most Cited Chinese Researchers in 2020 and 2021 by ELSEVIER, the world-renowned academic publisher.

Professor Jia is currently serving as Director of the School's Hong Kong Traditional Chinese Medicine Phenome Research Centre which is the first phenome centre working on Chinese medicine in the local and global contexts. Under his guidance, the Centre has attracted top global talents to conduct high-quality molecular and population-level translational research. Professor Jia is also spearheading the establishment of a research programme for the Scientific Evaluation of Chinese Tea, providing academic and research opportunities for students pursuing postgraduate study in this field.

Following the conferment of the Cheung On Tak Endowed Professorship in Chinese Medicine in 2020, Professor Jia has continued to promote the School's standing as a world-leading institute for Chinese medicine research. He has led collaborative projects with renowned institutions and professional bodies in Mainland China and overseas, spoken at international conferences and symposia as well as served on the editorial boards of prominent scientific journals.

張振海醫師榮獲「傑出服務表現獎」

張醫師是學院校友，於 2012 年加入學院，在教學科研部擔任技術導師，後獲晉升為臨床部中醫臨床助理教授並兼任部門副主任。多年來，他一直盡心盡力為學生、病人以及社會大眾提供卓越的服務。作為中醫骨傷科專家，他的醫術精湛，深受學生和病人的尊崇。

為了將中醫服務推廣至弱勢群體，張醫師帶領團隊與香港聖公會福利協會合作，並獲中國銀行（香港）慷慨捐助，推行為期三年的「中銀—浸大中醫社區中風預防及康復計劃」，為中風人士提供康復治療，並通過社區教育，降低老年人中風的發病率。該項目在2019 年第七屆亞太區安老創新大獎入圍總選名單，獲得國際間的認可。

疫情期間，張醫師出任浸大中醫抗疫醫療隊副隊長，並協助設立了遠程醫療中心，為超過41,000名病人及其密切接觸者提供免費診症服務。2022年3月，他帶領中醫師隊伍及學生到啟德暫託中心，為入住的輕症長者提供中醫治療。他亦參與組織長新冠中醫康復計劃，支援染疫人士復康。張醫師憑藉出眾的領導能力和竭力為病人服務的精神，獲得青少年抗疫連線的嘉許，並向他頒授感謝狀。

儘管工作繁重，張醫師仍然不遺餘力支持中醫藥各方面的發展。他積極參與中醫醫院轄下的規劃小組，為醫院的建設及設計出謀獻策；又擔任公營及非政府組織界別的委員會成員，為中醫藥行業的發展出力。此外，張醫師還參加了中醫如何幫助香港以至大灣區市民的討論，為民眾的健康謀福祉。

Mr. Cheung Chun-hoi wins President's Award for Outstanding Performance in Service

An alumnus of SCM who began his career in 2012 as Technical Instructor of CMTR, Mr. Cheung has been promoted to his current role as Assistant Professor of Practice and Associate Director in CLNC. During his tenure, he has shown steadfast dedication to providing top-quality service to his students, patients and the community at large. He is highly revered by his students and patients alike for his medical prowess as a specialist in orthopaedics.

In his bid to bring Chinese medicine healthcare services to the underprivileged people in the community, Mr. Cheung led a team to collaborate with the Hong Kong Sheng Kung Hui Welfare Council to secure a generous donation from the Bank of China (Hong Kong) for the three-year "BOC–HKBU Chinese Medicine Community Stroke Prevention and Rehabilitation Scheme", which provides rehabilitation treatments to post-stroke patients and offers community education to reduce the incidence of strokes among the elderly. This programme has gained international recognition, winning the Finalist Award in the 7th Asia Pacific Eldercare Innovation Awards in 2019.

During the pandemic, Mr. Cheung spearheaded several HKBU initiatives to assist in the fight against COVID-19. In his role as Associate Team Leader in the HKBU Chinese Medicine Team Against COVID-19, he assisted in establishing the telemedicine centre, which provided free consultation service and benefited more than 41,000 patients and their close contacts. In March 2022, he led a group of practitioners and students to provide Chinese medicine-based treatment services to elderly patients residing in the Kai Tak Holding Centre. He also participated in organising the Long COVID Chinese Medicine Rehabilitation Programme. In view of his excellent service and significant leadership, Mr. Cheung was presented with a Certificate of Appreciation by the Youth Anti-Coronavirus Link.

Despite his heavy workload, Mr. Cheung has been actively involved in the establishment and design of the Chinese Medicine Hospital (CMH), with participation in a variety of planning groups. He has also contributed to the development of the Chinese medicine industry by serving on committees in the public and NGO sectors. In addition, he is engaged in conversations on the ways in which Chinese medicine can assist the people of Hong Kong and the wider Greater Bay Area.

關曉儀博士獲頒「學院優秀教學表現獎」

關博士善於因材施教，按照學生不同的學習需要，為他們準備合適的教材，因此在過去五年的課程回饋問卷中都獲得很高的評分。此外，通過在《生物化學及分子生物學》科目中，結合生物化學和中醫的內容，她成功培育學生主動學習的能力，同時激發他們的創造力。作為一名終身學習者，關博士決定申請英國高等教育學會會士的資格，反映她重視自我發展，並視之為整個教學生涯的其中一項重要任務。

Dr. Kwan Hiu-yee receives School Performance Award in Individual Teaching

With her ability to identify her students' diverse learning needs and tailor-make teaching materials based on them, Dr. Kwan has earned a high score in Course Feedback Questionnaire over the past five years. Furthermore, by merging biochemistry and Chinese medicine in the Biochemistry and Molecular Biology course, she was able to cultivate her students' learning initiatives and creativity. As a lifelong learner, Dr. Kwan has made self-development one of her top priorities throughout her teaching career. This is evident in her decision to apply for the Higher Education Academy Fellowship.

劉進博士獲頒「學院優秀新晉研究學者獎」

劉博士是擁有骨科臨床背景的骨骼生物學家。作為新晉的研究員，他已取得豐富的研究成果，前途無限。他在探索肌肉骨骼疾病的新分子機制和藥物靶點方面的系列研究，已多次於《Nature Communications》、《Nature Aging》及《Biomaterials》等國際知名學術期刊發表。劉博士在該領域的重大發現，不僅為他贏得了分別由美國骨礦鹽研究學會及歐洲骨質疏鬆、骨關節炎和肌肉骨骼疾病臨床和經濟學會頒發的青年學者獎，更兩度成功獲得優配研究金。

Dr. Liu Jin receives School Performance Award as Early Career Researcher

A bone biologist with clinical background of orthopaedics, Dr. Liu has already emerged as an exceptional young researcher with remarkable accomplishments. His series of studies on exploring new molecular mechanisms and druggable targets of musculoskeletal disorders have been published in prestigious journals, such as *Nature Communications*, *Nature Aging*, and *Biomaterials*. Dr. Liu's groundbreaking findings in the field have not only earned him two Young Investigator Awards from the American Society of Bone and Mineral Research and European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases, but also secured him two research grants by General Research Fund.

韓全斌教授獲頒「學院優秀研究指導獎」

韓全斌教授是從事化學及草本多糖生物活性研究的知名學者。他熱衷於培育學生，自2011年加入教學科研部以來，合共指導了11名博士生、五名哲學碩士生，以及16名修課式研究生和八名本科生。在指導過程中，韓教授以助手身分參與學生的討論，協助他們作出決定，致力於培育他們的求知精神。他的其中一名博士畢業生已在浸大擔任研究助理教授，另有四名博士畢業生在香港和美國知名機構繼續博士後進修，例如在哈佛醫學院。

Professor Han Quanbin receives School Performance Award in Research Supervision

While being a reputed scholar of chemistry and the bioactivities of the herb polysaccharides, Professor Han is equally enthusiastic about his nurturing of students. Since joining CMTR in 2011, he has supervised 11 PhD students and five MPhil students as well as 16 taught postgraduate and eight undergraduate students. During his supervision, Professor Han is a helper for the students to discuss and make decisions together with students. This approach is essential to equipping students with an inquisitive mindset. One of his PhD students has taken up as a Research Assistant Professor at HKBU while four PhD students have advanced to postdoctoral training in renowned institutes in Hong Kong and US such as the Harvard Medical School.

浸大中醫抗疫遠程醫療中心支援團隊榮獲「非教學人員獎勵及嘉許計劃團隊獎」

隊長：臨床部中醫臨床教授孫鋒教授

在抗擊新冠疫情期間，浸大社群充分展現了團隊合作精神。學院臨床部於去年2月推出為患者或需要隔離的市民而設的遙距診症服務，此舉得到大學多個來自不同學術及行政部門的同事鼎力支持，令臨床部得以迅速設立遠程醫療中心、簡化採購防疫裝備的流程，以及建立預約和對外通訊系統，有效地提供快捷並順暢的診症服務。是次協作展示了浸大的團隊精神，攜手應對疫情帶來的挑戰，踐行服務社會的理念。

The Supporting Team for HKBU Chinese Medicine Telemedicine Centre Against COVID-19 wins Team Award of the Reward and Recognition Scheme for Non-teaching Staff

Leader:
Professor Sun Feng, Professor of Practice of CLNC

The HKBU community has really come together as one during the fight against COVID-19. CLNC of SCM took the initiative of offering tele-consultations to those diagnosed with the disease or under quarantine in February 2022. This move was strongly supported by colleagues from multiple academic and administrative units. They contributed to the efficient construction of the facilities, simplified the procurement of protective gear, and built booking and external communication systems that enabled efficient and fuss-free consultations to be provided. This collaborative effort has demonstrated how HKBU can face challenges bravely as a team.

啓德暫托中心支援團隊榮獲「非教學人員獎勵及嘉許計劃團隊獎」

隊長：臨床部中醫臨床助理教授張振海醫師

在第五波疫情期間，學院和來自不同部門的同事組成了浸大中醫抗疫醫療隊。團隊努力不懈，設立啟德暫託中心，成為該中心唯一的中醫服務提供者。團隊為超過100名病人提供中醫治療服務，並為中心內由靈實基督教協會及東華三院營運的病床提供處方中藥服務，給病患更多元化的治療選擇。團隊與駐場西醫、藥劑師、護士和社工，以及其他行政部門的同事攜手合作，不但提供了優質的隔離服務，抗擊疫情，其服務社會大眾的精神，更是浸大優秀團隊精神的典範。

The Supporting Team for the Kai Tak Holding Centre wins Team Award of the Reward and Recognition Scheme for Non-teaching Staff

Leader:
Mr. Cheung Chun-hoi, Assistant Professor of Practice of CLNC

During the fifth wave of the pandemic, the HKBU Chinese Medicine Team Against COVID-19 was formed by members of different departments. With their concerted efforts, the team built the Kai Tak Holding Centre, which became the sole Chinese medicine provider in the Centre. The team provided Chinese medicine-based treatment and prescription services respectively to over 100 patients and for the Centre's beds operated by the Haven of Hope Christian Service and Tung Wah Group of Hospitals, offering patients an alternative treatment option. By joining hands with the on-site doctors, pharmacists, nurses and social workers as well as staff from administrative units, the team not only provided a quality quarantine service to combat the pandemic, it was also an exemplar of how HKBU's excellent team spirit can serve the community.

學院領導研究發現腸易激綜合症新治療標靶

SCM-led research discovers new therapeutic target for irritable bowel syndrome



卞兆祥教授（中）、王凱亮博士（右）和翟李翔博士（左）的研究團隊首次發現人類腸道細菌「活潑瘤胃球菌」，是腹瀉型腸易激綜合症的主要觸發因素。

Professor Bian Zhaoxiang (middle), Dr. Xavier Wong (right) and Dr. Zhai Lixiang (left) has shown for the first time that the human gut bacterium *Ruminococcus gnavus* is a major trigger factor of diarrhoea-predominant irritable bowel syndrome.

由學院研究人員領導的一項研究，首次發現人類腸道細菌「活潑瘤胃球菌」，是腹瀉型腸易激綜合症的主要觸發因素，並根據這項發現，為該病症找到新的治療標靶。研究又發現，食用低蛋白含量食物如新鮮水果、蔬菜、麵包等，或有助減少腹瀉型腸易激綜合症出現的腸道蠕動。這項研究結果已發表於國際知名科學期刊《Cell Host & Microbe》。

腹瀉型腸易激綜合症未能根治

腸易激綜合症是常見的功能性腸病，特徵是大便不規律、腹部不適和腹脹。據估計，香港約有7%成年人受該病症影響。腹瀉型腸易激綜合症是該病症最常見的類型，並無根治方法，大多數臨床治療都集中於緩解症狀。

A study led by researchers from SCM has shown for the first time that the human gut bacterium *Ruminococcus gnavus* is a major trigger factor of diarrhoea-predominant irritable bowel syndrome (IBS-D). Based on this discovery, a new therapeutic target for the disease's treatment was identified. The study also found that low-protein food items such as fresh fruits, vegetables and bread may help reduce the gut motility in IBS-D. The research findings have been published in the internationally renowned scientific journal *Cell Host & Microbe*.

Curative treatment for IBS-D needed

Irritable bowel syndrome (IBS) is a common functional bowel disorder characterised by stool irregularities, abdominal discomfort and bloating. It has been estimated that about 7% of adults in Hong Kong are affected by IBS. IBS-D is the most common type of IBS and there is no known cure for the disease. Most clinical treatments for IBS-D focus on relieving symptoms.

血清素是調節腸道蠕動的主要神經傳導物質。以往研究顯示，增加製造血清素會導致腹瀉型腸易激綜合症的胃腸道症狀。此外，亦有研究顯示腸道微生物群在調節血清素水平方面能發揮作用。然而，當中涉及的細菌種類，以及腸道微生物群如何調節血清素製造的分子機制仍有待釐清。

「活潑瘤胃球菌」產生「苯乙胺」及「色胺」為誘發因素

為探討根治腹瀉型腸易激綜合症的方案，由曾肇添中醫藥臨床研究教授及臨床部主任卞兆祥教授、教學科研部助理教授王凱亮博士，以及學院博士後研究學人翟李翔博士共同領導的研究團隊，在290名患者的糞便樣本中，檢視了數千種食物成分及其分解物，發現他們的糞便含有大量苯乙胺和色胺。苯乙胺和色胺是由微生物消化膳食蛋白時所產生的微量芳香胺，並與腹瀉型腸易激綜合症的腹瀉症狀嚴重程度相關。

研究人員進一步發現，小鼠被餵食苯乙胺或色胺後，大便次數和結腸分泌物均有增加，而這些都是腹瀉型腸易激綜合症的主要症狀。

團隊又發現，在腹瀉型腸易激綜合症糞便樣本中大量存在腸道細菌「活潑瘤胃球菌」（Ruminococcus gnavus），而苯乙胺和色胺則主要由這種細菌製造。此外，把這種細菌移植到小鼠的腸道後，小鼠會出現腹瀉型腸易激綜合症的腹瀉症狀。這些結果顯示，由「活潑瘤胃球菌」製造的苯乙胺和色胺，可以在沒有其他風險因素下，在哺乳類動物誘發腹瀉型腸易激綜合症。

苯乙胺和色胺刺激血清素製造

研究團隊繼而進行一系列實驗，以了解苯乙胺和色胺導致腹瀉型腸易激綜合症的機制。結果顯示，苯乙胺和色胺通過激活「微量胺相關受體」 (TAAR1)，直接刺激腸道內的「嗜鉻細胞」產生血清素，繼而誘發腸道蠕動和分泌失調等腹瀉型腸易激綜合症的症狀。

Previous research has demonstrated that the increased production of serotonin, a key neurotransmitter involved in the regulation of gut motility, contributes to the gastrointestinal symptoms displayed in IBS-D. It has also been shown that gut microbiota play a role in regulating the levels of serotonin. However, the bacterial species concerned and the molecular mechanism by which the gut microbiota modulate serotonin production remain unclear.

Phenethylamine and tryptamine produced by *Ruminococcus gnavus* trigger IBS-D

To explore curative treatment options for IBS-D, a research team co-led by Professor Bian Zhaoxiang, Tsang Shiu Tim Endowed Professor in Chinese Medicine Clinical Studies and Director of CLNC; Dr. Wong Hoi-leong Xavier, Assistant Professor of CMTR; and Dr. Zhai Lixiang, Post-Doctoral Research Fellow of SCM, screened thousands of food components and their breakdown products in the fecal samples of 290 patients with IBS-D. They found that phenethylamine and tryptamine, two aromatic trace amines produced by the microbial digestion of dietary proteins, are highly enriched in IBS-D faeces, and they are associated with the severity of diarrheal symptoms in patients with IBS-D.

Probing further, the researchers found that mice which had been fed with either phenethylamine or tryptamine experienced increased stool frequencies and colonic secretions, which are major symptoms of IBS-D.

On the other hand, the team found that the gut bacterium *Ruminococcus gnavus*, which is enriched in IBS-D faecal samples, is a primary producer of phenethylamine and tryptamine. Furthermore, mice with this bacterium transplanted into their guts go on to develop IBS-D diarrheal symptoms. These results suggest that phenethylamine and tryptamine produced by *Ruminococcus gnavus* trigger IBS-D in mammals without the involvement of other risk factors of IBS-D.

Phenethylamine and tryptamine stimulate serotonin production

The research team further conducted a series of experiments to understand the mechanism by which phenethylamine and tryptamine lead to IBS-D. The results showed that phenethylamine and tryptamine directly stimulate the production of serotonin from the enterochromaffin cells in the gut through the activation of

團隊接着研究以「苯乙胺 / TAAR1通路」為標靶，治療腹瀉型腸易激綜合症的潛力。他們以移植了腹瀉型腸易激綜合症糞便樣本的小鼠作實驗，發現使用特定的抑制劑阻止 TAAR1被激活，能有效減輕腹瀉症狀。

新治療方案的前景

翟李翔博士指出：「我們的研究結果詳細描述了微生物群如何導致腸道蠕動失調的機制，並發現『苯乙胺 / 色胺 / TAAR1通路』是腹瀉型腸易激綜合症的新治療標靶。」

卞兆祥教授說：「腹瀉型腸易激綜合症的患者經常出現腹瀉及腹痛，令生活質素降低。研究的發現以抑制該通路為基礎，為發展出腹瀉型腸易激綜合症的新療法帶來希望。」

研究團隊還發現，低「苯丙氨酸」含量的飲食，可減少微生物產生苯乙胺和色胺，從而抑制小鼠的腸道蠕動。膳食中的苯丙氨酸是一種氨基酸，會被消化分解成苯乙胺。低蛋白含量食物如新鮮水果、蔬菜、麵包等，苯丙氨酸含量相對較低。

王凱亮博士表示：「制訂策略以減少微生物把膳食氨基酸轉化為苯乙胺和色胺，例如控制飲食，以減少攝取苯丙氨酸含量較高的高蛋白食品，或是控制腹瀉型腸易激綜合症的可行方法。」

a trace amine-associated receptor (TAAR1), thereby stimulating gut motility and secretion disorders in IBS-D.

The team then explored the therapeutic potential of targeting the phenethylamine/tryptamine/TAAR1 pathway for the treatment of IBS-D. It was discovered that inhibition of TAAR1 activation through the use of a specific inhibitor effectively alleviated the diarrheal symptoms in mice which had been transplanted with IBS-D faecal samples.

Prospects for new therapeutic options

"With a full outline of the mechanism of how gut microbiota associate with gut motility disorders, our research results suggest that the phenethylamine/tryptamine-mediated TAAR1 pathway is a new therapeutic target for IBS-D," said Dr. Zhai Lixiang.

"IBS-D patients experience frequent episodes of diarrhea with accompanying abdominal pain, which reduce the quality of life. The research discoveries offer promising potential for the development of therapies for IBS-D based on the inhibition of the pathway," said Professor Bian Zhaoxiang.

The research team also found that a diet low in phenylalanine, an amino acid and a dietary precursor of phenethylamine, suppresses gut motility in mice by reducing the microbial production of phenethylamine and tryptamine. Low-protein food items such as fresh fruits, vegetables and bread have relatively low levels of phenylalanine.

"Developing strategies to reduce the microbial transformation of dietary amino acids into phenethylamine and tryptamine, such as dietary intervention with reduced consumption of high-protein food items which usually have high phenylalanine levels, may represent a feasible approach for the management of IBS-D," said Dr. Xavier Wong.

學院領導研究揭示新冠病毒進入細胞機制及治療標靶

SCM-led research unveils cell entry mechanism of SARS-CoV-2 and therapeutic target for COVID-19



王凱亮博士（左）及郭軒銘博士（右）介紹有關新冠病毒進入細胞的機制及治療標靶的研究成果

Dr. Xavier Wong (left) and Dr. Guo Xuanming (right) introduce the research findings on the cell entry mechanism of SARS-CoV-2 and therapeutic target for COVID-19.

由學院研究人員領導的研究發現，一種名為 MT1-MMP 的蛋白酶，是決定「嚴重急性呼吸綜合症冠狀病毒2」（SARS-CoV-2，以下簡稱新型冠狀病毒）在人體內傳染的能力，並導致新冠感染影響不同器官的主要因素。研究團隊採用一種名為3A2的人源化抗體，以抑制 MT1-MMP 的活動，結果令受感染小鼠的病毒量減少近九成，證明 MT1-MMP 這種蛋白酶有條件成為治療2019冠狀病毒病的標靶。

是項研究成果已於國際知名科學期刊《Nature Communications》上發表。

ACE2作為新型冠狀病毒進入細胞的受體

接種疫苗可為人們提供保護，免受2019冠狀病毒病及其併發症的威脅，但它對免疫系統較弱的人士，或面

A study led by researchers from SCM has identified a protease called MT1-MMP that is a major host factor behind the infectivity of the SARS-CoV-2 virus in the human body, which leads to the infection of COVID-19 and multi-organ failure. By applying a humanised antibody called 3A2 that can inhibit the activity of MT1-MMP, the viral load of infected mice was reduced by almost 90%. The research team also demonstrated that the protease is a potential therapeutic target for COVID-19.

The research findings have been published in the internationally renowned scientific journal *Nature Communications*.

ACE2 as a receptor for SARS-CoV-2 cell entry

Vaccination can protect people against COVID-19 and its potential complications, but it is not always effective in individuals with weak immune systems, or against some COVID-19 variants of concern. Thus, the development of

對一些主要變種病毒時，並非經常有效。因此，開發更有效的新冠治療方案，在後疫苗時代仍然是一個巨大挑戰。了解新型冠狀病毒進入細胞的機制，對抑制病毒的傳播以及尋找新的新冠治療方案至為重要。

新型冠狀病毒需要「血管緊張素轉換酶2」（ACE2），作為其進入細胞的受體。ACE2是人類細胞膜上的蛋白質。雖然肺部是受新型冠狀病毒感染影響的主要器官，但ACE2只表現於少部分肺部細胞。

過去有研究發現，新型冠狀病毒依賴可溶性ACE2，也能感染只有少量ACE2表現的器官。可溶性ACE2與新型冠狀病毒結合，將病毒攜帶至只有少量ACE2表現的細胞，並幫助病毒進入這些細胞。

MT1-MMP 調節 SARS-CoV-2進入細胞

由教學科研部助理教授王凱亮博士帶領的研究團隊，與香港大學微生物學系助理教授袁碩峰博士合作，進一步研究產生可溶性ACE2的生理調節機制，與新冠病原的關係。

該團隊發現，感染新型冠狀病毒會導致更多MT1-MMP被激活。MT1-MMP是一種對許多生理過程十分重要的蛋白酶，會令可溶性ACE2從帶有ACE2的細胞中釋放出來。可溶性ACE2繼而與新型冠狀病毒的刺突蛋白結合，並將其運送至未受感染且只有少量ACE2表現的細胞。

值得注意的是，團隊證明把人類可溶性ACE2，注入因為體內ACE2與新冠病毒刺突蛋白不能結合，故先天性不容易受新冠病毒感染的實驗品種小鼠（C57BL/6小鼠），能夠令牠們的肺部受到感染。研究結果揭示了病毒「劫持」宿主酶，以增強其傳染性，及引發多器官感染的機制。

抗體3A2抑制 MT1-MMP 活動

為研究MT1-MMP的作用，以及它如何影響病毒感染，研究人員使用人類細胞培育「類器官」，即一種在體外培植的三維組織結構，用作在實驗室中模擬不同器官。

a more effective treatment for COVID-19 remains a huge challenge in the post-vaccine era. Understanding the cell entry mechanism of SARS-CoV-2 is vital to curb the spread of the virus, and it will also aid the search for new COVID-19 treatments.

SARS-CoV-2 requires angiotensin-converting enzyme 2 (ACE2), a protein found on the membrane of human cells, as its receptor for cellular entry. Despite the lungs being the major organ affected by SARS-CoV-2 infection, only a small proportion of lung cells express ACE2.

Previous studies found that the infection of organs with low levels of ACE2 expression by SARS-CoV-2 is made possible by a soluble form of ACE2. The soluble ACE2 binds with SARS-CoV-2, carries the virus to cells with low levels of ACE2 expression, and facilitates its entry into the cells.

MT1-MMP mediates cell entry of SARS-CoV-2

A research team led by Dr. Wong Hoi-leong Xavier, Assistant Professor of CMTR, in collaboration with Dr. Yuan Shuofeng, Assistant Professor of the Department of Microbiology at The University of Hong Kong, further studied how the physiological regulation of soluble ACE2 shedding contributes to the aetiology of COVID-19.

The team found that SARS-CoV-2 infection leads to the increased activation of MT1-MMP, a protease crucial for many physiological processes. MT1-MMP mediates the release of soluble ACE2 from ACE2-expressing cells. This soluble ACE2 in turn binds to the spike proteins of SARS-CoV-2 and carries it to the uninfected cells with low levels of ACE2 expression.

Notably, the team demonstrated that the introduction of human-soluble ACE2 enables SARS-CoV-2 to infect the lungs of a laboratory mouse strain (C57BL/6 mice) that is naturally insusceptible to SARS-CoV-2 infection due to the incompatibility of its mouse ACE2 and the viral spike proteins. The findings unveil the mechanism by which the virus hijacks host enzymes to enhance its infectivity, triggering multi-organ infections.

Antibody 3A2 blocks MT1-MMP activity

To study MT1-MMP's functions and how it affects viral infection, the researchers used human cells to create organoids, a 3D tissue structure grown *in vitro* to resemble and model different organs in the laboratory.

他們發現，使用單克隆抗體3A2抑制MT1-MMP的活動，能有效減少可溶性ACE2的水平，並將人類肺、心臟和肝臟類器官中新型冠狀病毒的感染程度，降低60%至80%。使用新型冠狀病毒的原始菌株，以及主要變種如Delta和Omicron進行實驗，也得到相約結果。研究結果顯示，MT1-MMP是人體內調節新型冠狀病毒進入細胞的主要因素，也是新冠藥物的潛在治療標靶。

研究人員進一步測試把3A2應用於受新冠感染小鼠的效果。在11隻小鼠之中，部份接受3A2治療，部份則作為對照組。由於高齡是新冠重症和死亡的主要風險因素，故實驗利用了老年小鼠進行。結果顯示，3A2把新型冠狀病毒的數量減少近90%，並顯著減輕由感染引起的肺組織破壞。

MT1-MMP 作為治療標靶

王凱亮博士說：「如何提高對免疫系統較弱患者的療效，以及維持藥物在不同病毒株中的效用，是開發新冠藥物的兩大挑戰。3A2有很好的潛力開發成治療新冠的有效藥物，因為它旨在抑制MT1-MMP的活動，而並非增強患者的免疫力，或直接對付病毒。」

「我們之前發表的研究，證明3A2還可預防肥胖和糖尿病，即新冠重症和死亡的兩個主要風險因素。因此，3A2可能特別適合高危群組，包括高齡和有代謝功能障礙的病人。它亦可能對未來的新發性冠狀病毒有效，因為對許多擁有類似細胞進入機制的病毒而言，ACE2都是它們的門戶。把3A2應用於人類之前，需作進一步的研究和實驗。」

They discovered that blocking MT1-MMP activity with the monoclonal antibody 3A2 effectively depleted soluble ACE2 levels and reduced the degree of infection of SARS-CoV-2 in human lung, heart and liver organoids by 60-80%. Consistent results were obtained using the original strain of SARS-CoV-2, as well as variants of concern, such as Delta and Omicron. The results demonstrate that MT1-MMP is a major host factor that mediates the cell entry of SARS-CoV-2, and that it is also a potential therapeutic target for COVID-19 drugs.

The researchers further tested the effects of applying 3A2 in a mouse COVID-19 model. A group of 11 mice were treated with either 3A2 or vehicle controls. Older mice were used in the experiment as old age is a major risk factor for severe symptoms and mortality for COVID-19. The results show that 3A2 reduced the viral load of SARS-CoV-2 by almost 90% and dramatically alleviated lung tissue damage resulting from infection.

MT1-MMP as a therapeutic target

Dr. Wong said: "Two major challenges when it comes to developing COVID-19 drugs are how to enhance treatment results for patients with weakened immune systems, and how to maintain the drugs' effectiveness across different viral strains. 3A2 has good potential to become an effective drug for curing COVID-19 because it antagonises the activity of MT1-MMP, instead of boosting the immunity of patients or acting directly on the virus."

"Our previous studies have demonstrated that 3A2 also offers protection against obesity and diabetes, two major risk factors for severe symptoms and mortality for COVID-19. Therefore, 3A2 could be particularly suitable for high-risk groups, including older adults and people with metabolic disorders. It could also be effective against emerging coronaviruses in the future, because ACE2 is a doorway for many such viruses with similar cell entry mechanisms. Further research and experiments on 3A2 are required before it can be applied in humans."

學院參與首屆「病證結合推動中西醫融合發展」學術研討會

SCM participates in the inaugural conference on "Integration of Disease–Syndrome to Promote the Synergistic Development of Traditional Chinese and Western Medicine"

照片來源：上海中醫藥大學
Photo Credit: SHUTCM

院長呂愛平教授及學院轄下的香港中醫藥表型組學研究中心主任賈偉教授於3月17日參加了由上海中醫藥大學主辦的首屆「病證結合推動中西醫融合發展」學術研討會。

會議上，中國科學院院士兼上海中醫藥大學原校長陳凱先院士發表了題爲「積極推動中西醫結合高質量發展」的演講，呂愛平教授及賈偉教授分別以「基於中西醫結合未來醫學的思考」及「代謝組學與精準健康」爲題發表演說。

五位專家包括陳凱先院士、上海中醫藥大學校長季光教授、呂愛平教授、賈偉教授，以及同濟大學生命科學與技術學院教授項耀祖教授，採用圓桌論壇的形式，一同探討傳統理論傳承創新、中藥現代化及中西醫結合診療模式改革等重要議題。

大會呼籲廣大同行共同致力於推動中西醫結合診療思維方法和實踐模式的創新，提升中西醫結合解決臨床複雜問題的能力和水平，爲維護人民健康作出貢獻。

學院將繼續關注中西醫結合領域的發展，通過學術交流與合作，積極參與推動中西醫結合事業的發展。/

Professor Lyu Aiping, Dean of Chinese Medicine, and Professor Jia Wei, Director of the School's Hong Kong Traditional Chinese Medicine Phenome Research Centre, spoke at the inaugural academic conference on "Integration of Disease–Syndrome to Promote the Synergistic Development of Traditional Chinese and Western Medicine" organised by Shanghai University of Traditional Chinese Medicine (SHUTCM) on 17 March.

At the conference, Professor Chen Kaixian, Academician of the Chinese Academy of Sciences and Former President of SHUTCM, delivered a speech titled "Actively Promoting the High-Quality Development of Integrated Traditional Chinese and Western Medicine." Professor Lyu Aiping shared his thoughts on "Future Medicine Based on the Integration of Traditional Chinese and Western Medicine," while Professor Jia Wei discussed "Metabolomics and Precision Health."

Five experts participated in a roundtable forum, including Professor Chen Kaixian; Professor Ji Guang, President of SHUTCM; Professor Lyu Aiping; Professor Jia Wei; and Professor Xiang Yaozu, Professor of School of Life Sciences and Technology at Tongji University. They discussed important topics such as innovation in the inheritance of traditional theories, modernisation of Chinese medicines, and reform of integrated traditional Chinese and Western medicine diagnostic and treatment models.

The conference called on colleagues to work together to promote innovative thinking and practice models in integrated traditional Chinese and Western medicine, improve the ability and level of integrated traditional Chinese and Western medicine to solve complex clinical problems, and contribute to safeguarding people's health.

SCM will continue to contribute to the development of the field of integrated traditional Chinese and Western medicine through academic exchange and collaboration./

Timothy John Mitchison 教授主講傑出學人講座

Professor Timothy John Mitchison inspires faculty and students at Distinguished Lecture

學院於去年11月21日舉辦傑出學人講座，邀得 Timothy John Mitchison 教授擔任講者。大學在同日舉行頒授典禮，向 Mitchison 教授授予榮譽博士學位。

Mitchison 教授的講座題為「微管藥物如何發揮治療作用？」，闡述紫杉烷、秋水仙鹼等靶向微管聚合動態的細小分子藥物，如何在人體中發揮治療功效。近150名浸大科研人員及研究生親身或透過 Zoom 出席講座，一探 Mitchison 教授在細胞生物學和藥理學科研前沿領域取得的傲人成果。

Mitchison 教授是享譽盛名的細胞生物學家和系統生物學家。他現任哈佛大學哈西卜・薩巴格系統生物學講座教授，更是哈佛大學化學和細胞生物學研究所所長及聯合創辦人。他和研究所的同事率先利用基於表型的藥物篩選技術，用「高通量」方法有效「敲除」沒用的遺傳成分，從而加快將這一技術落實應用為治療方法。他亦獲公認為細胞擾動工具的創造者，相關工具用於記錄亞細胞環境中的模式化反應，以及研發治療方法。

Mitchison 教授在多醣和新型藥物傳遞方面，與學院的研究人員緊密合作，全力支持相關研究。/

SCM hosted a Distinguished Lecture on 21 November 2022, featuring Professor Timothy John Mitchison who was conferred with the degree of Doctor of Science, *honoris causa*, by the University at a ceremony held on the same day.

Titled "How do microtubule drugs act as medicines?", Professor Mitchison's lecture elucidated how small molecule drugs such as taxanes and colchicine that target the polymerisation dynamics of microtubules act therapeutically in the human body. Around 150 scientists and research students at HKBU attended the lecture in person or via Zoom to gain insights into Professor Mitchison's world-leading research in cell biology and pharmacology.

Professor Mitchison is an acclaimed cell biologist and systems biologist. He is currently the Hasib Sabbagh Professor of Systems Biology at Harvard University. He is also the director and co-founder of the Institute for Chemistry and Cell Biology at Harvard, in which he and his colleagues first piloted phenotype-based drug-screening techniques, whose "high-throughput" volume established the necessary "knockouts" of unwanted genetic constituents, hence accelerating prototyping for therapeutic development. He is duly credited as the creator of the tools of perturbation used to document patterned responses in subcellular environments as well as for their refinement for therapeutic applications.

Professor Mitchison is a close collaborator and supporter for research on polysaccharide and novel drug delivery with researchers at SCM. /

專家探討基層醫療中的綜合肌骨痛症管理

Experts explore integrated musculoskeletal pain management in primary care

學院聯同香港中西醫結合醫學會及中西醫醫學平台主辦的「中西醫基層醫療肌骨痛症」研討會於3月26日在校園圓滿舉行。本次研討會由院長呂愛平教授和香港中西醫結合醫學會榮譽會長余秋良醫生領導的會議組織委員會策劃，開幕典禮的主禮嘉賓包括醫務衞生局基層醫療健康專員彭飛舟醫生、香港立法會議員（醫療衞生界）林哲玄醫生、安老事務委員會主席李國棟醫生，以及香港中文大學賽馬會公共衞生及基層醫療學院醫療管理學專業應用教授熊志添教授。是次活動吸引逾 500 名醫護專業人士及公眾參與。

彭飛舟醫生在開幕典禮上致辭時表示，基層醫療健康辦事處正構思更新有關肌肉骨骼疾病的參考概覽，以便將更多中西醫合作的成分融入其中，並在基層醫療網絡上更好地實施中西醫共同治理方案。

林哲玄醫生強調了中醫藥的傳承及創新發展：「疫情之後，香港社會對中醫的需求更加殷切。財政司司長在2023/24年度的財政預算案中，答應額外投入5億發展中醫藥。我有信心，這一定有助中醫藥進一步發展，以及中西醫醫學協作，令更多市民得益。」

是次研討會涵蓋多個主題，包括肌肉骨骼疼痛、頭痛、基層醫療中常見的腰痛和膝關節骨關節炎的治理，運用針灸、局部麻醉劑注射藥物及水中太極對痛症的治療和成效，以及如何達致舒穩適身模式，以促進健康和提高生活質量。 /

SCM jointly hosted a seminar on "Integrative Musculoskeletal Pain Management in Primary Care" with the Hong Kong Association for Integration of Chinese-Western Medicine (HKAIM) and Integrative Joint Organization Platform (IJOP) on campus on 26 March. The event was organised by a committee led by Professor Lyu Aiping, Dean of Chinese Medicine and Dr. Edwin Yu, Honorary President of HKAIM. The seminar was attended by more than 500 medical professionals and members of the public.

Dr. Pang Fei-chau, Commissioner for Primary Healthcare of the Health Bureau, addressed the audience at the opening ceremony, highlighting the Primary Healthcare Office's initiative to update its "Reference Framework" for common musculoskeletal problems in primary care settings. The goal is to incorporate a greater degree of Chinese-Western medicine collaboration and efficiently implement joint approaches within primary healthcare networks, ultimately contributing to improved patient care.

Dr. Hon David Lam Tzit-yuen, Legislative Council Member (Medical and Health Services), underscored the importance of preserving the traditions and promoting innovative development in Chinese medicine. He pointed out that, "in the wake of the Covid-19 pandemic, the demand for Chinese medicine in Hong Kong has become increasingly urgent. The Financial Secretary committed to invest HK$500 million in the development of Chinese medicine in the 2023/24 Budget. I am confident that this investment will not only bolster the growth of Chinese medicine but also foster collaboration between Chinese and Western medicine practitioners, ultimately benefiting the wider public."

The seminar covered a range of topics, including management of musculoskeletal pain, headaches, lower back pain and knee osteoarthritis; use of acupuncture, local anaesthetics injections and aquatic Tai Chi for pain treatment and relief; and how to be "snug and fit" to promote well-being and improve the quality of life. /

浸大委任呂愛平教授為副校長（研究及拓展）

HKBU appoints Professor Lyu Aiping as Vice-President (Research and Development)

浸大校董會於6月13日通過委任黃英豪博士中醫藥教授暨中醫藥學院院長呂愛平教授為副校長（研究及拓展），由8月1日生效。呂教授是適配子轉化醫學及藥物研發領域的世界頂尖科學家，自2012年加入浸大以來，他一直憑卓越的領導才能推動學院持續發展。

呂教授的研究興趣主要為中醫藥學與系統醫學，特別是類風濕性關節炎的創新分類與新藥研發。多年來，他成功獲得本地、區內以至國家資助機構的大量研究撥款。他曾發表600多篇論文，取得60多項專利，其「谷歌學術」引用次數接近24,000次，最新的「谷歌學者 H 指數」為76。呂教授是中醫診斷標準化的代表性人物，屢獲殊榮。

浸大校長衞炳江教授歡迎呂教授的任命，並指出：「在呂教授的傑出學術生涯中，他一直走在跨學科研究的前沿，致力結合傳統中醫藥和其他生物醫學領域。他在學術領導和提升研究實力方面成就卓著，必定能帶領浸大於跨學科研究再創高峰。」

作為副校長（研究及拓展），呂教授將領導大學的整體研究策略、研究撥款策略、研究基礎設施和研究生教育的發展。他亦會協助大學推動多學科和跨學科研究，並領導研究團隊爭取參與校外的大型研究項

呂教授欣然接受任命：「能夠擔任副校長一職，我深感榮幸。在未來的時間，我希望營造一個充滿活力的科研氛圍，促進我們優秀教職員之間的創新、合作和卓越實績。」 /

The HKBU Council approved on 13 June the appointment of Professor Lyu Aiping, Dr. Kennedy Y.H. Wong Endowed Professor in Chinese Medicine and Dean of Chinese Medicine, as Vice-President (Research and Development), with effect from 1 August. A world-leading scientist in aptamer-based translational medicine and drug discovery, Professor Lyu joined HKBU in 2012 and has provided excellent academic leadership for the ongoing development of SCM.

Professor Lyu's research interests focus on Chinese medicine and systems medicine, particularly the rheumatoid arthritis and its novel classification and new drug discovery. Over the years, he has successfully secured numerous research grants and funding supported by local, regional and national funding bodies. He has published more than 600 articles and obtained over 60 patents, as well as achieved high Google Scholar citation counts of around 24,000, with a recent Google Scholar H-index score of 76. Professor Lyu is a leading figure in the standardisation of Chinese medicine diagnosis, and his distinguished accomplishments have been widely recognised by the numerous awards and prizes he has received.

Professor Alexander Wai, President and Vice-Chancellor of HKBU, welcomes the appointment and said, "Throughout his distinguished academic career, Professor Lyu has been at the forefront of promoting transdisciplinary research which integrates traditional Chinese medicine with other biomedical disciplines. His remarkable achievements in academic leadership and capacity building for research activities will definitely contribute to the strengthening of HKBU's transdisciplinary research strategy."

As Vice-President (Research and Development), Professor Lyu will lead the development of the University's overall research strategy, research funding strategy, research infrastructure and postgraduate education. He will support the University in driving multidisciplinary and transdisciplinary research, and lead research teams in securing large extramural research projects.

Professor Lyu is pleased to accept the appointment: " It is an honor to assume this position. In my term of office, I hope to foster a vibrant research culture that nurtures innovation, collaboration, and excellence among our highly talented faculty members." /

賈偉教授當選歐洲科學院院士

Professor Jia Wei elected Member of Academia Europaea

張安德中醫藥教授暨副院長（國際合作）賈偉教授最近獲歐洲科學院選為生理學與神經科學學部院士，以表彰他在代謝與生理學領域的非凡貢獻。歐洲科學院成立於1988年，是一所在歐洲有廣泛代表性的科學、人文和文學學院。該學院的5,000多名院士均為頂尖的科學家和學者，當中包括83位諾貝爾獎得主。作為首位內地及香港代謝組學專家學者獲此殊榮，賈教授表示興奮，並指出未來工作將會集中於構成疾病表型的整體代謝和免疫變化，期望從中尋找發病機制，發現新的藥物作用通路和靶點。/

Professor Jia Wei, Cheung On Tak Endowed Professor in Chinese Medicine and Associate Dean (International Collaboration) of Chinese Medicine, has recently been elected as a Member of the Academia Europaea (Physiology & Neuroscience section) in recognition of his exceptional contributions to the field of metabolism and physiology. Established in 1988, the Academia Europaea is the pan-European Academy of Sciences, Humanities and Letters. It comprises over 5,000 distinguished scientists and scholars, including 83 Nobel Prize laureates. As the first metabolism expert and scholar from Mainland China and Hong Kong to receive this honor, Professor Jia expressed excitement and stated that he will focus on the overall metabolic and immune changes that constitute disease phenotypes. He hopes to identify the pathogenesis and discover new drug action pathways and targets through his research./

張敬浩博士獲頒授冠名副教授席

Dr. Cheung King-ho conferred endowed associate professorship

教學科研部副教授張敬浩博士於今年獲頒「吳文政中醫藥副教授」榮銜。張博士是細胞訊號、分子神經科學及神經退行性疾病專家，他於2017年加入浸大，致力推進中藥的臨床應用，並與團隊研發出治療阿茲海默症的中藥新複方——「神經防禦方」，此複方正在中國及美國申請專利。上述冠名教授席在吳文政王月娥基金會的慷慨支持下成立，以促進中醫藥研究的發展及國際化，並進一步提升中醫藥在現代醫學界的地位。/

Dr. Cheung King-ho, Associate Professor of CMTR, was appointed as the Vincent V.C. Woo Endowed Associate Professor in Chinese Medicine this year. Joined HKBU in 2017, Dr. Cheung is an expert in cell signalling, molecular neuroscience and neurodegeneration and is dedicated to advancing traditional Chinese medicine clinical application. His team has developed a novel treatment for Alzheimer's disease, NeuroDefend, which has been filed as a patent in the China and the US. Supported by the generosity of Vincent and Lily Woo Foundation, this endowed associate professorship was established to help advance the development and internationalisation of Chinese medicine as well as to elevate its status in modern medicine./

澳門行政長官到訪中藥創新研發中心

Chief Executive of Macao visits Centre for Chinese Herbal Medicine Drug Development

澳門特別行政區行政長官賀一誠先生在2月25日到訪位於科學園的中藥創新研發中心，了解中心的研究項目和實驗室設施，並與浸大代表交流。浸大校長衞炳江教授、協理副校長（中醫藥發展）兼中心總裁卞兆祥教授、副院長（國際合作）賈偉教授，以及中心特別顧問兼澳門中藥研發中心主任王一濤教授，接待到訪的澳門和香港政府代表。訪問期間，卞教授向來賓介紹中心成立的背景、研發平台、研發目標等，並帶領來賓參觀實驗室。 /

Mr. Ho Iat-seng, Chief Executive of the Macao Special Administrative Region, visited the Centre for Chinese Herbal Medicine Drug Development (CDD) at the Hong Kong Science Park on 25 February to learn more about the Centre's research projects and laboratory facilities, and discuss the sector with HKBU representatives. Professor Alexander Wai, President and Vice-Chancellor of HKBU; Professor Bian Zhaoxiang, Associate Vice-President (Chinese Medicine Development) and Director of CDD; Professor Jia Wei, Associate Dean (International Collaboration) of Chinese Medicine, together with Professor Wang Yitao, Special Advisor of CDD and Director of the Macao Centre for Research and Development in Chinese Medicine, received the government representatives from Macau and Hong Kong. During the visit, Professor Bian introduced the background of the Centre's establishment, its R&D platforms, and its objectives to the guests, as well as led them on a laboratory tour. /

國家藥品監督管理局代表訪問學院

National Medical Products Administration delegates visit SCM

國家藥品監督管理局（藥監局）副局長趙軍寧先生率領8人代表團於2月14日訪問學院。浸大校長衞炳江教授、暫任首席創新總監劉樂庭教授、院長呂愛平教授、臨床部主任兼中藥創新研發中心總裁卞兆祥教授，以及學院代表與藥監局代表團就中醫藥的創新和發展交流意見。代表團亦於同日參觀了中藥創新研發中心。中心是獲香港特別行政區政府創新科技署「InnoHK 創新香港研發平台」資助的綜合性中藥藥物研發中心。 /

An eight-member delegation from the National Medical Products Administration (NMPA), led by Mr. Zhao Junning, NMPA Deputy Commissioner, visited SCM on 14 February. Professor Alexander Wai, President and Vice-Chancellor of HKBU; Professor Terence Lau, Interim Chief Innovation Officer; Professor Lyu Aiping, Dean of Chinese Medicine; Professor Bian Zhaoxiang, Director of CLNC and of CDD, and SCM representatives exchanged views with the NMPA delegation on issues relating to the innovation and development of Chinese medicine. The delegation also visited CDD, the integrated Chinese medicine drug research and development centre supported by the InnoHK scheme under the Innovation and Technology Commission of the HKSAR Government, on the day. /

張宏杰教授的專利發明獲優秀獎

Professor Zhang Hongjie's patented invention wins excellence award

教學科研部主任張宏杰教授的專利發明「基於石斛屬成分的皮膚保護組合物」榮獲2022年粵港澳大灣區高價值專利培育佈局大賽中戰略性支柱產業集群的優秀獎。比賽由廣東省市場監督管理局（知識產權局）、香港特別行政區政府知識產權署、澳門特別行政區政府經濟及科技發展局和佛山市人民政府聯合舉辦，旨在發掘技術領先及市場潛力龐大的專利創新項目，推動高價值專利培育佈局，並促進粵港澳大灣區向高增值知識型經濟發展。/

The patented invention titled "Skin-protection composition containing dendrobium-based ingredients" developed by Professor Zhang Hongjie, Director of CMTR, won the Excellence Award in the strategic pillar enterprise category of the Guangdong-Hong Kong-Macao Greater Bay Area High-value Patent Portfolio Layout Competition 2022. Co-organised by the Guangdong Administration for Market Regulation (Guangdong Intellectual Property Administration), the Intellectual Property Department of the HKSAR Government, the Economic and Technological Development Bureau of the Macao SAR Government, and the People's Government of Foshan Municipality, the competition aims to uncover innovative patent projects with leading technology and great market potential, promote high-value patent portfolio layouts, and stimulate the development of a knowledge-based and high value-added economy within the Guangdong-Hong Kong-Macao Greater Bay Area. /

于媛媛博士在日內瓦國際發明展奪獎

Dr. Yu Yuanyuan clinches award at Geneva International Exhibition of Inventions

教學科研部助理教授于媛媛博士的創新科研項目在「2023年日內瓦國際發明展」榮獲銀獎。她及其研究團隊設計了一種以硬骨抑素loop3為標靶的獨特適配子，用以治療骨質疏鬆症，能有效抑制硬骨抑素的作用，在骨質疏鬆動物實驗中能促進骨骼形成，而不會增加患心血管疾病的風險。日內瓦國際發明展是全球創新科技界的年度盛事，由專家評審團對來自超過40個國家/地區及超過1,000個線上線下的項目進行評審。/

Dr. Yu Yuanyuan, Assistant Professor of CMTR, won a Silver Medal at the 2023 Geneva International Exhibition of Inventions for her innovative research project. The research team designed a specific aptamer targeting sclerostin loop3 as a treatment for osteoporosis, which effectively inhibits sclerostin's antagonistic effects, thus promoting bone formation in osteoporotic animal models without increasing the risk of developing cardiovascular diseases. The Geneva International Exhibition of Inventions is a signature annual global event devoted exclusively to inventions. More than 1,000 inventions (online and on-site) from more than 40 countries or regions were evaluated by a panel of professional judges. /

浸大與華潤簽署中成藥研究合作備忘錄

HKBU and China Resources sign MOU on proprietary Chinese medicine research

浸大與華潤江中及華潤科學技術研究院在去年12月7日簽署合作意向書，進行以參靈草改善新冠後遺症的研究。在簽署儀式暨交流會上，浸大協理副校長（中醫藥發展）兼臨床部主任卞兆祥教授講述大學在中醫藥領域的最新發展和研究成就，而華潤醫藥首席執行官白曉松先生和華潤雙鶴董事長于順廷先生則介紹華潤醫藥的研究和發展方向，以及重點產品。憑藉協議各方的競爭優勢，預料將會在中醫藥科技創新及新產品發展方面帶來更多合作機會。/

The University signed a Memorandum of Understanding (MOU) with CR Jiangzhong and the China Resources Research Institute of Science & Technology on 7 December 2022 to reach an understanding on research into *shenlingcao* for treating post-COVID-19 syndrome. At the signing ceremony-cum-seminar, Professor Bian Zhaoxiang, Associate Vice-President (Chinese Medicine Development) of HKBU and Director of CLNC, gave an overview of the University's recent developments and research achievements in Chinese medicine. Mr. Bai Xiaosong, CEO of China Resources Pharmaceutical Group Limited, and Mr. Yu Shunyan, Chairman of China Resources Double-Crane Pharmaceutical Company Limited, shared the research and development initiatives as well as the signature products of the China Resources Pharmaceutical Group. By leveraging the signing parties' competitive advantages, more collaboration opportunities in Chinese medicine technological advancement and business incubation are expected. /

中藥創新研發中心與北京同仁堂合作研發中藥

CDD and Beijing Tong Ren Tang collaborate to develop Chinese medicinelong COVID

中藥創新研發中心與北京同仁堂國藥有限公司在1月4日簽署合作意向書，以中藥複方為基礎進行合作研究。簽署儀式上，雙方代表分別介紹浸大和北京同仁堂的研究領域和交流合作方向，以共同建立合作科研平台為目標，把傳統中藥複方結合先進技術，將科研成果轉化發展新藥物。雙方並會結合教研資源，建立專業人才培養計畫，以提升合作平台的實力，並培育本地研究中醫藥的人才。/

The Centre for Chinese Herbal Medicine Drug Development (CDD) signed a MOU with Beijing Tong Ren Tang Chinese Medicine Company Limited on 4 January to conduct collaborative research based on Chinese medicine formulas. During the MOU signing ceremony, both parties introduced their research domains and discussed the direction for further cooperation, with the objectives of cultivating a collaborative drug research platform for advancing traditional Chinese medicine formulas with technologies and translating research outputs into new drugs. They will join hands to provide a talent grooming programme that will support the research platform and nurture local Chinese medicine research talent. /

學院獲捐贈港幣400萬元設立洪瑞德中醫藥臨床研究基金

SCM received a donation of HK$4M to establish “Chinese Medicine Clinical Research Fund”

香港浸會大學（浸大）於4月18日舉行「洪瑞德演講廳命名典禮」，以答謝天寶集團控股有限公司主席、執行董事兼行政總裁暨洪瑞德基金創辦人洪光椅先生慷慨捐贈港幣400萬元，用以設立「中醫藥臨床研究基金」，支持浸大中醫藥學院進行有關中風的臨牀研究，讓更多長者和有需要的人士受惠。命名典禮由洪光椅先生及浸大校長衞炳江教授主禮。衞炳江教授致辭時表示承蒙洪先生及其家人的鼎力支持，大學能為學生提供最佳的學習體驗，並在研究工作上更臻卓越。」/

HKBU named the Andrew Hung Lecture Theatre on 18 April, after a generous donation of HK$4 million from Mr Hung Kwong-yee, Chairman of Ten Pao Group Holdings Limited. The donation will establish the “Chinese Medicine Clinical Research Fund” to support stroke clinical research by the School of Chinese Medicine at HKBU, benefiting the elderly and those in need. The naming ceremony was officiated by Mr Hung Kwong-yee and Professor Alexander Wai, President and Vice-Chancellor of HKBU. “HKBU is in a stronger position to offer our students the best learning experience, and take forward its pursuit of research excellence”, said Professor Wai./

浸大喜獲名駒集團支持新冠病毒感染患者中醫康復計劃

HKBU launches Famous Horse Chinese Medicine Rehabilitation Programme for COVID-19 Patients

香港浸會大學最近喜獲名駒集團有限公司捐資港幣200萬元，聯同中醫藥學院推出名駒新冠病毒感染患者中醫康復計劃。合資格的患者可獲免費診症服務及藥物。/

HKBU received a generous donation of HK$2 million from Famous Horse Holdings Limited to launch the Famous Horse Chinese Medicine Rehabilitation Programme for COVID-19 Patients in collaboration with the School of Chinese Medicine (SCM). Under the Programme, eligible patients will be provided with free consultation services and medicine./

中醫藥發展基金資助學院微電影《中醫藥道》

The Chinese Medicine Development Fund sponsors School's microfilm Path to Chinese Medicine

上集 Episode 1

下集 Episode 2

為協助市民了解中醫師培訓、執業情況及其權限，增強大眾對年青中醫師的信心，我院獲中醫藥發展基金資助港幣75萬元，夥拍浸大傳理學院合作製作了一輯微電影《中醫藥道》，電影分為上下兩集，並在浸大 Youtube 頻道播放。影片以短劇形式描述香港中醫師的現況，能以輕鬆手法向大眾傳播中醫藥行業資訊。 /

Our school has received a HKD 750,000 grant from the Chinese Medicine Development Fund to increase public understanding of the training, practice, and authority of Chinese medicine practitioners and to boost confidence in young practitioners. We collaborated with the School of Communication to produce two episodes of microfilm titled 'Path to Chinese Medicine', which can be viewed on HKBU's YouTube channel. The microfilms feature young people depicting the current situation of Chinese medicine practitioners in Hong Kong and delivering industry information to the public in an engaging and relaxed manner. /

獅子會慈善基金十五周年慈善晚宴

CMCF 15th Anniversary Fundraising Dinner

「獅子會與香港浸會大學中醫藥慈善基金」於2022年12月16日舉行「龍的傳人釣魚台之夜」慈善晚宴。是次慈善晚宴所籌得善款合共港幣一百萬元正，全數撥給「長者愛心診症咭計劃」和其他相關服務，向更多有需要的長者提供中醫藥服務。慈善基金亦藉此機會致送感謝狀予累積捐款逾一百萬元的捐款者，包括屯門獅子會、海外捐款、國際獅子總會中國港澳三〇三區、孔憲紹慈善基金及林海涵博士，JP，以感謝他們多年來對基金的鼎力襄助。 /

The Lions and Hong Kong Baptist University Chinese Medicine Charity Foundation hosted a fundraising dinner officiated by various dignitaries, raising HKD 1 million for the "Privilege Scheme of Chinese Medicine Service for Elderly" and related services. Donors with over HKD 1 million in accumulated donations were also recognized, including Lions Club of Tuen Mun, Lions Clubs International District 303 – Hong Kong & Macao, China, Hung Hin Shiu Charitable Foundation Ltd., and Dr. Lam Hoi Ham, JP. /

浸大中學校長日加強與中學的溝通

HKBU's Secondary School Principals' Day 2023

本年度的浸大中學校長日於2月1日舉行，約二十位來自本港不同中學的校長和老師出席中醫藥互動工作坊，學院藉此機會向與會者介紹中醫藥教育的課程特色及升學詳情。學院師生於導賞環節帶領參加者參觀中醫藥大樓的各項設施，包括教學實驗室、中醫藥圖書館、中醫專科診所、中醫博物館及中藥標本中心，加深了解中醫藥學生的學習生活。參加者更可參加穴位推拿學習坊及中藥學習坊，親身體驗及動手學習中醫藥相關知識。/

Around 20 principals and teachers from different secondary schools attended the HKBU Academic Registry's organized Principals' Day 2023 on 1st February. The event aimed to showcase the unique features of Chinese Medicine education offered by SCM and included a guided tour of the School's facilities such as teaching laboratories, the Chinese Medicine Library, the Chinese Medicine Specialty Clinic, and the Museum of Chinese Medicine. Attendees also participated in hands-on activities like acupuncture and Chinese medicine authentication demonstrations, improving communication between SCM and secondary schools./

海外本科課程推廣——馬來西亞

Overseas Recruitment Event - Malaysia

經歷三年的疫情，大學收生處決定今年重辦海外招生活動。教學科研部副教授余堅文博士代表學院於4月10至13日前往馬來西亞的教育展，向檳城三所中學的學生及教職員推廣中醫藥本科課程及收生資訊。/

Following a three-year hiatus due to the COVID-19 pandemic, the Admissions Office resumed organizing overseas recruitment events this year. Dr. Kevin Yue, Associate Professor of CMTR, represented the School at an Education Fair in Malaysia from 10-13 April. Two undergraduate programs have been promoted during the exhibition - Bachelor of Chinese Medicine and Bachelor of Science (Hons) in Biomedical Science, and Bachelor of Pharmacy (Hons) in Chinese Medicine. Briefings on admission requirements were also given to three secondary schools./

中小學生中醫藥課程

SCM promotes Chinese Medicine to local primary and secondary students

本學年，學院分別與油麻地天主教小學、拔萃女書院、聖保祿中學及粉嶺救恩書院合作開辦中醫藥課程，為對中醫藥有濃厚興趣的中小學生提供了學習機會，內容涵蓋中醫藥的歷史與發展、中醫和中藥的概念、經絡穴位認識及中醫藥在日常生活中的應用。/

This academic year, SCM continued promoting Chinese Medicine courses to local primary and secondary students who have great passion for Chinese Medicine. Collaborating schools included Yaumati Catholic Primary School, Diocesan Girls' School, St. Paul's Convent School (Secondary Section) and Fanling Kau Yan College. The courses covered a range of topics, including Chinese Medicine history, basic concepts, knowledge of acupoints and application of Chinese Medicine./

中學生參觀本校中草藥園及職業博覽講座

Herbal Garden Visit and Career Expo

本學年，本校為粉嶺救恩書院及聖保祿學校安排參觀中醫博物館及中草藥園，並由本校導師向同學親自講解不同中草藥植物的品種、功效及栽培方法，讓學生親身接觸不同植物，加深學生對中草藥的了解。此外，職業博覽會為天水圍官立中學的年度活動。今年的職業博覽會吸引了超過400名中三至中六的學生，當中不乏對中醫藥行業感興趣的同學，他們都積極提問，希望為將來報讀中醫藥專業課程做好準備。/

SCM arranged museum and herbal garden visits this academic year for students at St. Paul's Convent School (Secondary Section) and Fanling Kau Yan College to deepen their understanding of Chinese Medicine. Our instructors introduced different Chinese herbal plants, its characteristics and cultivation methods. This year, the Career Expo attracted over 400 students from Form 3 to Form 6, who expressed great interest in the industry's development and actively participated in the event to prepare themselves for enrolling in the Chinese Medicine and Pharmacy program. /

浸會大學僱主午餐會2023

HKBU Employers' Luncheon 2023

2月，大學成功舉辦了兩次本科生和研究生的僱主午餐會。午餐會旨在加強大學與各個行業的聯繫，兩次聚會吸引了超過500位來自本地和國際企業代表參加。在午餐會上，中藥學院的三年級學生辛忠奕分享了他大學生活以及中醫學院的課程如何幫助學生的未來發展。/

In February, the University organized two successful Employers' Luncheons for undergraduates and research postgraduates. These networking events aimed to enhance the University's ties with different industries and attracted over 500 potential employers from both local and international corporates. During the Luncheons, SENG Zhong Yi, Amos, a Year 3 student from the School of Chinese Medicine, shared his well-rounded university experience and how the SCM programme has prepared him for the future. /

持續及專業教育部舉辦修課式碩士學位課程簡介會

DCPE organizes information seminar on taught postgraduate programmes

持續及專業教育部於 1 月 7 日舉辦修課式碩士學位課程簡介會，該簡介會於線上線下同步舉行。部門教師在會上詳細闡述四個修課式碩士學位課程的課程目標、課程結構、教學內容、入學要求和申請程序等。在問答環節，參會人員反應熱烈，積極發問及留言，與教師們充分互動。是次課程簡介會成功加深了參會人員對學院的四個修課式中醫藥碩士學位課程的認識。/

The Division of Continuing and Professional Education (DCPE) organized a hybrid information seminar for the four taught postgraduate programmes on 7 January. During the seminar, programme teachers introduced the program objectives and its structure, course contents, and application information. Attendees actively participated in the Q&A session, raising questions that were addressed in detail by the teachers. The seminar was considered an effective platform to promote the programmes and motivate prospective students to submit applications. /

中醫骨傷服務學習及虛擬實體教學平台

Applying Virtual Reality to Virtual Teaching and Learning in Traditional Chinese Medicine Education (Orthopedics and Trauma)

本年度的骨傷科課題獲得教學發展及語文培訓補助金資助港幣100萬元發展虛擬實體教學。項目與香港中文大學中醫學院和香港大學中醫藥學院合作，進行爲期兩年的服務學習及虛擬實體教學活動。學生在進行服務學習後，需要以服務對象為藍本創作劇本，用以建立 VR 虛擬實體教學平台。平台將會以學生製作的教材為本傳承下去，讓往後的學生也能夠向師兄姐學習，真正實踐「前人種樹，後人乘涼」的宗旨。本計劃目的在於提升學生對於醫德的反思及鞏固骨傷知識，在 VR 平台上學習解難能力及對病案的分析思考能力，然後在服務學習活動中對真實病人應用，再而練習實際骨傷手法，達到課室學習與實踐的平衡。/

The Orthopedics and Trauma course of the School of Chinese Medicine has successfully applied for the Teaching Development and Language Enhancement Grant with a 2-year inter-institutional project titled *Applying Virtual Reality to Virtual Teaching and Learning in Traditional Chinese Medicine Education (Orthopedics and Trauma)*. HKD$1,000,000 is granted for the project development. As a leading institution, HKBU is collaborating with The Chinese University of Hong Kong and the University of Hong Kong to enhance project impact. The project starts from 2021-2022 to the 2023-2024 academic year, including at least 2 service-learning activities and developing a virtual reality learning platform featuring gamification elements. The new initiative follows the motto of 'to sow the seeds of our future success'. Participating students from each year are required to write the scripts and design the 'game' and content for the VR platform after their service learning. The educational materials produced will not only exchange among the participating students but also pass down to the next batch of students. The coming group of students will then be able to learn from their academic seniors through the previous scripts and contribute the skills learned to the patients. The project creates a tight-knit and contributive academic loop for a new teaching method./

透過服務學習幫助市民舒緩長新冠症狀

Alleviating the Long COVID Symptoms through service-learning in School of Chinese Medicine

新冠疫情歷時三年，社區中有不少受長新冠影響的患者，中西醫學界仍在積極進行長新冠的相關研究。同時，受疫情影響，香港中西醫療界廣泛應用遙距診症，形成了新常態。隨著防疫措施逐步放寬，實體服務學習得到恢復，結合遙距診症的普及，以及線上服務學習的成功經驗，兩者相輔相成，將會促使服務學習的成效更為超卓。本服務學習提供主動學習機會予學生，融入中醫臨床，讓學生了解當代香港社會受長新冠影響的患者的狀況，思考如何運用中醫知識改善患者生活素質；同時透過線上隨訪及保健教學，關顧患者的身心健康。學生從實際患者的觀察結合中醫知識和思考得出之保健方法，將透過社交平台分享予市民大眾，使受眾更廣。/

Society has been grappling with the effects of COVID-19 for the past three years. While a considerable amount of Chinese and Western medical research is still underway regarding long COVID, the number of patients suffering from its symptoms cannot be overlooked. Online consultations have been widely used in both the Chinese and Western medicine sectors during pandemic. As local anti-epidemic measures have gradually loosened, face-to-face service-learning has been reinstated. Building on the success of the past online service-learning experience and the popularity of online consultations, service-learning is expected to be even more effective. Its aim is to provide students with an active learning opportunity to immerse themselves in the clinical environment, better understand the challenges faced by long COVID patients, and think about how to improve their quality of life by using the knowledge of Chinese medicine. Additionally, students can provide physical and mental health care to patients through online consultations and daily health care sharing. Health care advice based on clinical observations and Chinese medicine theory can be spread through social platforms./

中醫診斷學服務學習

Service Learning on Diagnostics of Chinese Medicine

3月，教學科研部首席講師李紅博士及技術導師陳子晴小姐帶領中醫一年級學生進行服務學習，安排長者到訪大學參觀中醫藥博物館、中醫藥工作坊，普及中醫四診、體質、穴位知識，與長者共同度過快樂充實的下午。/

In March, Dr. LI Hong and Ms. CHAN Tsz Ching of CMTR organized service-learning event for BCM year 1 students. They arranged for the elderly to visit the university to tour the Chinese Medicine Museum and participate in Chinese Medicine workshops, spreading knowledge about the four diagnoses of Chinese medicine, constitution, and acupoint information. The students and elderly spent a happy and fulfilling afternoon together. /

針灸學社區服務學習

Service Learning on Acupuncture

教學科研部首席講師李紅博士及技術導師黎弘毅醫師帶領中醫三年級學生到訪黃大仙榕光社進行服務學習，運用課堂學習的針灸學知識，針對長者常見不適，在2至3月期間探訪並教導長者自我按穴和體質分析，長者高度讚揚同學專心學業，協助他們舒緩症狀。 /

In Feburary to March, Dr. LI Hong and Mr. LAI Hong Yi of CMTR led a group of year 3 students to visit Wong Tai Sin Yung Kwong Social Service Centre for service-learning from February to March. Applying acupuncture knowledge learned in class, they visited and taught the elderly self-acupressure and constitution analysis. The elderly praised the students for their diligent studies and appreciated their assistance in alleviating their symptoms. /

MHM 學生向本港中學生推廣健康生活知識及中醫文化

MHM Students promotes Chinese medicine culture to secondary school students

中醫健康管理理學碩士課程的77名同學應本港7間中學邀請前往開展健康生活知識推廣活動。同學們精心準備了11個活動主題，在各間中學進行展示，生動活潑的演示和互動深受中學師生歡迎。同時，近80名中四及中五學生應邀前來浸大校園參觀。碩士同學向中學生們現場介紹了孔憲紹博士伉儷中醫藥博物館、中國銀行（香港）中藥標本中心和藥用植物園中的展品及藥材，幫助同學們了解中醫文化和近距離體驗浸大中醫藥專業的學習氛圍。這一系列活動於2022年12月至2023年4月開展。通過活動，同學們豐富了課程學習體驗及實現了將所學知識服務他人的願望。/

More than 70 Master of Science in Personal Health Management (Chinese Medicine) (MHM) students were invited to attend health promotion activities in 7 local secondary schools. They prepared 11 themes and presented them in lively demonstrations, which were welcomed by secondary students and teachers. Additionally, nearly 80 local Form 4 and Form 5 students visited the HKBU campus, where MHM students explained exhibits and medicinal materials in various Chinese medicine facilities. The series activities ran from December 2022 to April 2023, enriching students' learning experiences and fulfilling their desire to serve others. /

學院參與「香港國際生物科技展」展示研究成果

SCM Showcases Research Achievements at BIOHK2022

中醫藥學院獲邀參加2022年香港國際生物科技展。展會期間，呂愛平院長發表了關於生物科技與中醫藥現代化的主旨演講（Biotechnology in Chinese Medicine Modernization）。同時，學院派出六個傑出的轉化醫學研究團隊的代表在中醫藥學院專屬展台向全球生物科技與醫藥業界人士、投資人以及公眾充分展現了學院近年來在中醫藥現代化和藥物發現領域取得的卓越科研成果與轉化案例。/

The School of Chinese Medicine showcased its research achievements at the Hong Kong International Biotechnology Exhibition. During the exhibition, Dean Lyu Aiping delivered a keynote speech on biotechnology and modernization of Chinese medicine. The School also sent representatives from six outstanding translational medicine research teams to showcase its remarkable research achievements and translational cases in the modernization and drug discovery of Chinese medicine to global biotech and pharmaceutical industries, investors, and the public. /

陳偉教授受媒體邀請與公眾分享提升正氣貼士

Prof. Chen Wei shares tips on improving immune system with media and public

香港的口罩令已解除多時，但仍有部份人士外出時會配戴口罩。浸大中醫藥學院中醫臨床教授陳偉認為，為融入正常「無罩」生活，提升自身抵抗力尤其重要，如正氣不足，難以避免感染疾病。他建議可從定時作息、適量運動、均衡飲食，並結合四季養生和穴位艾灸提升正氣。/

Despite the lifting of mandatory mask-wearing requirements in Hong Kong, many people continue to wear masks in public areas. Professor Chen Wei from the HKBU School of Chinese Medicine, stresses the importance of improving our immune system to return to a "mask-free" life. He recommends maintaining a regular routine of work and rest, engaging in moderate exercise, and consuming a balanced diet, as well as practicing seasonal well-being and receiving moxibustion therapy to strengthen overall health and immunity./

浸大中醫日贈醫施藥　市民踴躍參加

Chinese Medicine Community Day: Free Chinese Medical Consultant

由臨床部籌辦的年度盛事——浸大中醫日於5月1日在轄下八間診所順利舉行，活動當天吸引逾八百位市民參加，反應熱烈。成功預約人士可於當日接受免費健康諮詢和治療，並獲贈兩劑中藥。一如往年，雷生春的訪客更可免費品嚐診所職員準備的涼茶。/

On 1 May, SCM held its annual Chinese Medicine Community Day at eight of the HKBU clinics, drawing over 800 applicants. The event provided free medical consultations and treatments, including two doses of Chinese medicine per person, to those who successfully registered for the services. As in previous years, visitors to the Lui Seng Chun clinic were also treated to free herbal drinks prepared by the clinical staff./

學院新春茶聚聯繫各界

School of Chinese Medicine's Spring Reception strengthens ties with stakeholders

學院在2月12日舉辦新春茶聚，與大約120名嘉賓，包括政府官員、業界友好、校友和師生共賀新歲。校長衞炳江教授致歡迎辭時，感謝各界多年以來，尤其在抗疫期間對學院和大學的支持。他希望與持份者繼續緊密合作，以確保香港首間中醫醫院順利投入服務，發揮中醫藥發展的「旗艦」及「轉化者」角色。/

SCM held a Spring Reception on 12 February to celebrate the Chinese New Year with around 120 guests, including government officials, industry members, alumni, faculty members and students.Professor Alexander Wai, President and Vice-Chancellor, expressed his gratitude to the guests for their staunch support of SCM and the University over the past few years and during the fight against COVID-19. To ensure the smooth commencement of service of Hong Kong's first Chinese Medicine Hospital (CMH), he pledged to work closely and continuously with all stakeholders so that the Hospital can play the key role of "flagship" and "change driver" in the development of Chinese medicine. /

學院在集思會上探索未來方向

SCM explores future directions and gathers insights at Retreat

學院於6月9日在香港海洋公園萬豪酒店舉辦了一場具啟發性的集思會，邀得60多名同事共同探討本科教育、研究與企業合作、持續及專業教育，以及臨床服務等範疇。當天活動伊始，由學院副院長（教與學）李敏教授致開會詞，隨後與會者圍繞課程改進、以影響力為導向的校企合作案例，以及激活臨床服務與教學之間聯繫等話題展開了精彩的討論。是次集思會促進了來自不同年代、熱衷於推動中醫藥事業發展的與會者交流對話，極具意義。同事們對集思會在三年的歇息之後得以復辦表示歡迎。/

SCM hosted a thought-provoking retreat on 9 June at Hong Kong Ocean Park Marriott Hotel, bringing together over 60 colleagues to discuss various aspects of undergraduate education, research and industry collaboration, continuing and professional education, as well as clinical services.The day began with a warm welcome from Professor Li Min, Associate Dean (Teaching and Learning) of Chinese Medicine, and was filled with engaging discussions on topics such as potential curriculum improvements, cases of university-industry cooperation driven by impact, and activation of the nexus between clinical services and teaching.The retreat proved to be a valuable experience, fostering dialogue among participants from different generations who share a passion for advancing Chinese medicine to new heights. Colleagues all appreciated the resumption of the Retreat after a three-year hiatus. /

學院舉辦「篤信力行 浸心抗疫」展覽

SCM stages exhibition titled "Faith and Perseverance: HKBU's All-round Care amid COVID-19"

學院由6月1 日起至11月30日在孔憲紹博士伉儷中醫藥博物館舉辦以「篤信力行 浸心抗疫」為題的展覽，呈現於2019冠狀病毒病第五波疫情期間，浸大中醫抗疫醫療隊所作出的努力及取得的經驗，分享臨床及研究成果，同時介紹中醫藥抗疫小知識，進一步向社會推廣中醫藥在抗擊疫情上所發揮的正面作用。展覽期間，浸大李棕博士中醫藥圖書館亦同步推介新冠肺炎相關館藏書籍。/

SCM has staged an exhibition titled "Faith and Perseverance: HKBU's All-round Care amid COVID-19" at the Dr. & Mrs. Hung Hin Shiu Museum of Chinese Medicine, which will be running until 30 November. This exhibition showcases the efforts made and experiences gained by the HKBU Chinese Medicine Team Against COVID-19 during the fifth wave of the COVID-19 pandemic in Hong Kong, shares the clinical and research results, as well as introduces some Chinese medicine tips for COVID-19, with a view to promoting to society the positive impacts of Chinese medicine in combating the pandemic.To complement the exhibition, Dr. Stephen Riady Chinese Medicine Library at Hong Kong Baptist University is also introducing the books related to COVID-19 in the library. /

學院在畢業典禮上祝賀 2023 年畢業班

SCM celebrates Class of 2023 at Commencement

學院於6月1日為本科和修課式研究生課程的學生舉辦首次以學院為本的畢業典禮，超過300名畢業班同學及600名嘉賓參加。學院院長呂愛平教授在向畢業班致詞時，勉勵畢業班同學要具備適應力、同理心和終身學習的能力。隨著畢業典禮各項儀式展開，2023年畢業班同學一同紀念他們在校園的時光，同時展望光輝的未來。SCM organised the first School-based Commencement for students from its undergraduate and taught postgraduate programmes on 1 June, which was attended by over 300 graduating students and 600 guests. In his address to the graduating class, Professor Lyu Aiping, Dean of Chinese Medicine, encouraged the graduating students to be resilience, empathetic and lifelong learners. As the ceremonial procedures unfolded, the Class of 2023 commemorated their time on campus and looked ahead to bright futures. /

本科生胡仕楠獲頒香港生命科學獎學金

Undergraduate student Kenny Woo receives Hong Kong Life Sciences Scholarship Award

中醫本科二年級學生胡仕楠榮獲2022/23年度香港生命科學獎學金，表揚他在學業上的優異成績。香港生命科技青年會早前設立了「香港生命科學獎學金計劃」，支持在教資會資助大學攻讀生命科學或生物醫學課程的優秀本科生，並提供師友和實習計劃，幫助學生融入生命科技行業。BCM Year 2 student Kenny Woo Shi-nam was recently honoured with the 2022/23 Hong Kong Life Sciences Scholarship Award in recognition of his outstanding academic achievements. Hong Kong Life Sciences Society established the Hong Kong Life Sciences Scholarship Awards to encourage exceptional undergraduate students to pursue life sciences or biomedical science programmes at UGC-funded universities, and offered mentorship and internship programmes to help young talents integrate into the life sciences sector. /

中醫健康管理理學碩士畢業生於創業大賽獲優秀獎

MHM graduates win excellence award at entrepreneurship contest

由三名中醫健康管理理學碩士學位課程畢業生范駿、楊欣慧和劉雨晴組成的團隊，在「第三屆中國康復醫學會康復醫學教育創新創業大賽」中獲頒優秀獎。本屆比賽以「融合創新，智慧康復」為主題，吸引了全國21所高校共83支隊伍參賽，展示全國各院校康復教育成果與創新創業的教學理念，共同推動康復教育領域的創新發展。A team comprising three graduates of the Master of Science in Personal Health Management (Chinese Medicine) (MHM) programme, Fan Jun, Yang Xinhui and Liu Yuqing, won an Excellence Award at the 3rd Innovation and Entrepreneurship Competition for Rehabilitation Medicine Education, organised by the Chinese Association of Rehabilitation Medicine. Themed "Innovative Integration, Intelligent Rehabilitation," the competition attracted 83 teams from 21 universities across China and showcased the achievements of rehabilitation education as well as innovative and entrepreneurial teaching concepts from various universities in China, thus jointly pushing forward the innovative development in the field of rehabilitation education. /

中藥學會於花卉展奪最佳設計優異獎

Society of Chinese Materia Medica wins Merit Award for Design Excellence at Flower Show

中藥學會於3月10至19日參加由康樂及文化事務署主辦的香港花卉展覽。學會以「清熱解毒及祛濕中草藥」為題，展出多種具有藥用價值的中草藥，並獲得本地展品組「最佳設計優異獎」。The Society of Chinese Materia Medica participated in the Hong Kong Flower Show organised by the Leisure and Cultural Services Department from 10 to 19 March. Carrying the theme of "Heat, Toxic and Damp-clearing Herbs," the Society displayed a collection of herbs with medicinal value, and won the Merit Award for Design Excellence in the Local Displays Section. /

中醫藥學會新一屆幹事會就職典禮

Inauguration of the new executive committee of the Chinese Medicine Society

中醫藥學會第二十五屆幹事會於4月12日舉行就職典禮。各幹事會成員在學院教職員、同學，以及業界和其他學生組織代表的見證下，承諾盡心服務會員，並積極推廣中醫藥文化。The 25th Executive Committee of the Chinese Medicine Society held its inauguration ceremony on 12 April. In the presence of faculty members, fellow students, representatives from the industry and other student societies, the new committee pledged to serve the members of the Society and promote Chinese medicine with all their hearts and to the best of their ability. /

學會舉辦聯校中醫學術講座

Student societies organise joint school academic seminars

浸大中醫藥學會及中藥學會聯同香港大學和香港中文大學的學生組織合辦了兩場聯校中醫學術講座。首場講座於2月舉行，邀得胡沛峰醫師分享閱讀中醫古代文獻對學習中醫的重要性；而次場講座則於3月舉行，邀得林振邦博士、李顯揚醫師和歐樂貽醫師分享他們在本科學習時遇到的困難和體會，以及提供生涯規劃建議。The Chinese Medicine Society and the Society of Chinese Materia Medica joined hands with the student societies at HKU and CUHK to organise two academic seminars. In February, Mr. Hu Peifeng was invited to deliver a talk on the importance of reading ancient Chinese medical prose for learning Chinese medicine, while Dr. Lam Chun Pong, Mr. Li Hin-yeung and Ms. Au Lok-yi shared in March the difficulties and experience they encountered during their undergraduate studies, as well as gave advice on career planning. /

呂海濤博士 Dr. Lyu Haitao

教學科研部副教授
Associate Professor, Teaching and Research Division

呂博士於黑龍江中醫藥大學取得生藥學博士學位，再赴美國愛因斯坦醫學院、華盛頓大學醫學院和麻省理工學院等擔任博士後研究員，其後任職於重慶大學和上海交通大學。呂博士的主要研究方向為下一代功能代謝組學應用於生命健康交叉科學。他曾主持國家重點研發計劃等課題 10 多項，並於 2021 年分別獲選為英國皇家化學會及英國皇家生物學會會士。

Dr. Lyu obtained his PhD in Pharmacognosy from Heilongjiang University of Chinese Medicine, and received postdoctoral training from Albert Einstein College of Medicine, Washington University School of Medicine and MIT SMART Centre. After that, he worked at Chongqing University and Shanghai Jiao Tong University. Dr Lyu's research focuses on next-generation functional metabolomics in life and health sciences. He has led over 10 research projects at national level, and was elected Fellow of the Royal Society of Chemistry and of the Royal Society of Biology in 2021.

陳錦華博士 Dr. Chan Kam Wa

教學科研部助理教授
Assistant Professor, Teaching and Research Division

陳博士為香港浸會大學中醫學學士及生物醫學理學士 (榮譽)、中醫學碩士（中醫內科）、倫敦衛生及熱帶病學院公共衛生理學碩士、廣州中醫藥大學中醫醫學博士及香港大學哲學博士（內科），曾到訪格羅寧根大學醫學中心深造個體化臨床研究及參與新型糖尿病藥物之研發，並於 2023 年獲委任為助理教授。陳博士主要從事傳染病、呼吸系統疾病、糖尿病、慢性腎病及其他內科疾病的中西醫協作臨床、臨床研究及轉化研究。

Chris received clinical Chinese medicine training from the HKBU (BCM&BSc, MCM), Tung Wah Group of Hospitals (clinical training) and Guangzhou University of Chinese Medicine (MD); clinical epidemiology, personalized medicine and internal medicine training from the London School of Hygiene & Tropical Medicine (MSc Public Health), University Medical Center Groningen (overseas training), Queen Mary Hospital and HKU (PhD). Chris was appointed as Assistant Professor in 2023. Chris mainly engaged in integrative clinical services, clinical research and translation research of infectious disease, respiratory disease, diabetes, chronic kidney disease, and other internal medicine conditions.

林振邦博士 Dr. Lam Chun Pong

教學科研部二級講師 Lecturer II, Teaching and Research Division

林博士於香港浸會大學取得中醫學學士及生物醫學理學士（榮譽）雙學位，後獲北京中醫藥大學頒發碩士及博士學位，並取得香港中文大學中醫癌症治療專業文憑。林博士具香港註冊中醫及國家執業中藥師資格，主要從事中醫經典、道地藥材臨床藥學、中醫醫史文獻的教學與研究工作，其臨床專業包括中醫內科、腎病與京幫中藥。

Dr. Lam graduated from HKBU with a Bachelor of Chinese Medicine and Bachelor of Science (Hons) in Biomedical Science double-degree. He then earned a master's degree and PhD degree from Beijing University of Chinese Medicine as well as a Professional Diploma in Chinese Medicine Cancer Treatment from CUHK. A registered Chinese medicine practitioner in Hong Kong and licensed pharmacist of Chinese medicine in China, Dr. Lam's teaching and research areas include Chinese medicine classics, geo-authentic herbs and clinical Chinese materia medica, and history and literature of Chinese medicine. His clinical expertise includes internal medicine, nephrology, and Jingbang materia medica.

王穎詩醫師 Ms. Wang Yingshi

臨床部中醫臨床助理教授

Assistant Professor of Practice, Clinical Division

王醫師畢業於廣州中醫藥大學，取得中醫學士學位。她來港前在廣州市番禺區中醫院擔任中醫內科主治醫師，具有超過 10 年臨床工作經驗。王醫師曾參加廣州市區級新技術推廣項目，並發表多篇學術論文。

Ms. Wang graduated from Guangzhou University of Traditional Chinese Medicine with a bachelor's degree in traditional Chinese medicine. Before coming to Hong Kong, she worked as an attending physician of traditional Chinese medicine at Panyu Hospital of Traditional Chinese Medicine, Guangzhou, and possesses over 10 years of clinical experience. Ms. Wang has participated in a district-level new technology promotion project in Guangzhou and published several academic papers.

朱源興醫師 Mr. Zhu Yuanxing

臨床部中醫臨床助理教授

Assistant Professor of Practice, Clinical Division

朱醫師畢業於廣州中醫藥大學，其後完成公立醫院住院醫師輪科培訓及中醫全科醫師規範化培訓，熟悉各科常見疾病的中西醫診療。自 2018 年起在香港從事中醫臨床工作，並取得香港大學中醫學碩士學位（腫瘤學）。朱醫師的研究範疇為中藥應用於腫瘤疾病和慢性疾病的治療。

Mr. Zhu graduated from Guangzhou University of Traditional Chinese Medicine and completed resident physician rotation training and standardised training for general practitioners of traditional Chinese medicine in public hospitals. He is familiar with Chinese and Western medicine diagnosis and treatment of various diseases. He has been engaged in Chinese medicine clinical work in Hong Kong since 2018, and obtained a master's degree in Chinese medicine (oncology) from The University of Hong Kong. Mr. Zhu's research focuses on the application of Chinese herbal medicine in the treatment of oncological diseases and chronic diseases.

《浸大中醫醫案系列6：壺天擷英》

主編：呂愛平、卞兆祥

醫案對中醫藥教育發展有着深遠的影響，是中醫師臨床治病救人的真實紀錄，同時是中醫經驗傳承的核心部份，有助承先啟後，對培養中醫人才極其重要。本書是《浸大中醫醫案系列》的最新一冊，在郭鍾寶芬慈善基金的慷慨支持下出版，內容包括四診資訊、辨證立法及處方用藥等範疇，涵蓋中醫臨床各科的知識、醫師的學術思想、診治經驗和心得。



《中藥材鑒定圖典》（越南文版）

作者：趙中振、陳虎彪

中藥鑒定為中藥標準化的基礎，也是中藥國際化的前提。本書結合編者和團隊30年來的本草文獻研究、海內外植物基源考察、藥材市場調查和實驗室研究所得的第一手資料編著而成，收錄四百多種常用中藥材和飲片的鑒別特徵。此書先以繁體中文和簡體中文出版，隨後被英、日、韓、德、俄、越的專家學者翻譯，並由當地出版社發行。



聯絡我們
Contact Us

香港浸會大學中醫藥學院
九龍塘浸會大學道七號賽馬會中醫藥學院大樓

School of Chinese Medicine, Hong Kong Baptist University
Jockey Club School of Chinese Medicine Building,
7 Baptist University Road, Kowloon Tong, Kowloon.

院長辦公室 Dean's Office
四樓 4/F
電話 Tel (852) 3411 2457
傳真 Fax (852) 3411 2917
電郵 Email scmd@hkbu.edu.hk

教學科研部 Teaching and Research Division
四樓 4/F
電話 Tel (852) 3411 2481
傳真 Fax (852) 3411 2461
電郵 Email cmtr@hkbu.edu.hk

技術開發部 Technology Development Division
四樓 4/F
電話 Tel (852) 3411 2945
傳真 Fax (852) 3411 2902
電郵 Email scmtdd@hkbu.edu.hk

臨床部 Clinical Division
三樓 3/F
電話 Tel (852) 3411 2968 / (852) 3411 2988
傳真 Fax (852) 3411 2929
電郵 Email scmcld@hkbu.edu.hk

持續及專業教育部 Division of Continuing & Professional Education
四樓417室 Rm417, 4/F
電話 Tel (852) 3411 2912 / (852) 3411 5748
傳真 Fax (852) 3411 2918
電郵 Email dcpe@hkbu.edu.hk

秘書處 Secretariat
四樓 4/F
電話 Tel (852) 3411 5387
傳真 Fax (852) 3411 2902
電郵 Email scm@hkbu.edu.hk

學院網頁 | SCM Website
http://scm.hkbu.edu.hk

學院 IG | SCM IG
hkbuscm

學院 FB | SCM FB
scm.hkbu